Aspergillus and candida infections in bone marrow transplantation: Progress and controversies

Infectious Diseases in Clinical Practice

Volumn 6, Issue 8, 1997, Pages 506-512

  Revankar, Sanjay G ^a   Patterson, Thomas F ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE;

ASPERGILLOSIS; BONE MARROW TRANSPLANTATION; CANDIDIASIS; HUMAN; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; REVIEW; RISK FACTOR; TREATMENT CONTRAINDICATION;

EID: 0030706106     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199706080-00003     Document Type: Review

References (65)

1. Hiemenz JW, Greene JN. Special considerations for the patient undergoing allogeneic or autologous bone marrow transplantation. Hematol Oncol Clin North Am 1993; 7:961-1002.
2. Hunter AE, Haynes AP, Russell NH Bone marrow transplantation: current situation, complications and prevention. J Antimicrob Chemother 1995;36(Suppl B):119S-33S.
3. Rossetti F, Brawner DL, Bowden R, et al. Fungal liver infection in marrow transplant recipients: prevalence at autopsy, predisposing factors, and clinical features Clin Infect Dis 1995;20:801-11.
4. Hagensee ME, Bauwens JE, Kjos B, et al. Brain abscess following marrow transplantation: experience at the Fred Hutchinson Cancer Research Center, 1984-1992. Clin Infect Dis 1994;19:402-8.
5. Pannuti CS, Gingrich RD, Pfaller MA, et al. Nosocomial pneumonia in adult patients undergoing bone marrow transplantation: a 9-year study. J Clin Oncol 1991;9:77-84.
6. Iwen PC, Reed EC, Armitage JO, et al. Nosocomial invasive aspergillosis in lymphoma patients treated with bone marrow or peripheral stem cell transplants. Infect Control Hosp Epidemiol 1993;14:131-9.
7. Uzun O, Anaissie EJ. Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal. Blood 1995;86:2063-72.
8. Momin F, Chandrasekar PH. Antimicrobial prophylaxis in bone marrow transplantation. Ann Intern Med 1995;123: 205-15.
9. Morrison VA, Haake RJ, Weisdorf DJ. The spectrum of non-candida fungal infections following bone marrow transplantation. Medicine (Baltimore) 1993;72:78-89.
10. Saral R. Candida and aspergillus infections in immunocompromised patients: an overview. Rev Infect Dis 1991; 13:487-92.
11. Tritz DM, Woods GL. Fatal disseminated infection with Aspergillus terreus in immunocompromised hosts. Clin Infect Dis 1993;16:118-22.
12. Morrison VA, Haake RJ, Weisdorf DJ. Non-candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med 1994;96:497-503.
13. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis 1990;12:1147-1201.
14. Burch PA, Karp JE, Merz WG, et al. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol 1987;5:1985-93.
15. Aoun M, Van der Auwera P, Gerain J, et al. Aspergillosis in the immunocompromised: focus on treatment. Recent Results Cancer Res 1993;132:127-36.
16. Sanchez C, Mauri E, Dalmau D, et al. Treatment of cerebral aspergillosis with itraconazole: do high doses improve the prognosis? Clin Infect Dis 1995;21:1485-87.
17. Kintzel PE, Rollins CJ, Yee WJ, et al. Low itraconazole serum concentrations following administration of itraconazole suspension to critically ill allogeneic bone marrow transplantation recipients. Ann Pharmacother 1995; 29:140-3.
18. Bowden RA, Cays M, Gooley T, et al. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996;173:1208-15.
19. Kruger W, Stockschlader M, Russman B, et al. Experience with liposomal amphotericin B in 60 patients undergoing high-dose therapy and bone marrow or peripheral blood stem cell transplantation. Br J Haematol 1995;91:684-90.
20. Ringden O, Tollemar J, Dahllof G, et al. High cure rate of invasive fungal infections in immunocompromised children using AmBisome. Transplant Proc 1994;26:175-77.
21. Andstrom EE, Ringden O, Remberger M, et al. Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients. Mycoses 1996;39:185-93.
22. Todeschini G, Murari C, Bonesi R, et al. Oral itraconazole plus nasal amphotericin B for prophylaxis of invasive aspergiliosis in patients with hematological malignancies. Eur J Clin Microbiol Infect Dis 1993;12:614-8.
23. O'Donnell MR, Schmidt GM, Tegtmeier BR, et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high risk patients. J Clin Oncol 1994;12:827-34.
24. Riley DK, Pavia AT, Beatty PG, et al. The prophylactic use of low dose amphotericin B in bone marrow transplant patients. Am J Med 1994;97:509-14.
25. Beyer J, Schwartz S, Barzen G, et al. Use of amphotericin B aerosols for the prevention of pulmonary aspergillosis. Infection 1994;22:143-8.
26. Tollemar J, Ringden O, Andersson S, et al. Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients. Transplant Proc 1993;25:1495-7.
27. Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992;165: 891-7.
28. Zukerman JM, Tunkel AR. Itraconazoie: a new triazole antifungal agent. Infect Control Hosp Epidemiol 1994;15: 397-410.
29. Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994;97:135-44.
30. Trigg ME, Menezes AH, Giller R, et al. Combined antifungal therapy and surgical resection as treatment of disseminated aspergillosis of the lung and brain following BMT. Bone Marrow Transplant 1993;11:493-96.
31. Goldberg SL, Geha DJ, Marshall WF, et al. Successful treatment of simultaneous pulmonary Pseudallescheria boydii and Aspergillus terreus infection with oral itraconazole. Clin Infect Dis 1993;16:803-5.
32. Patterson TF, Kirkpatrick WR, White M, et al. Therapy of invasive aspergillosis: disease spectrum, treatment practices and outcomes [abstract LM38]. In: Proceedings and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 15-18, 1996; New Orleans (LA). Washington (DC): American Society for Microbiology, 1996:287.
33. Persat F, Marzullo C, Guyotat D, et al. Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. Eur J Cancer 1992;28A:838-41.
34. Van de Velde VJS, Van Peer AP, Heykants JJP, et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-β-cyclodextrin formulation of itraconazole. Pharmacotherapy 1996;16:424-8.
35. Vreugdenhil G, Van Dijke BJ, Donnelly JP, et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma 1993;11:353-8.
36. Morgenstern GR, Prentice AG, Prentice HG, et al. Itraconazole oral solution vs fluconazole suspension for antifungal prophylaxis in neutropenic patients [abstract LM34]. In: Proceedings and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 15-18, 1996; New Orleans (LA-).Washington (DC): American Society for Microbiology, 1996:286.
37. Saah D, Drakos PE, Elidan J, et al. Rhinocerebral aspergillosis in patients undergoing bone marrow transplantation. Ann Otol Rhinol Laryngol 1994;103:306-10.
38. Coleman JM, Hogg GG, Rosenfeld JV. Invasive central nervous system aspergillosis: cure with liposomal amphotericin B, itraconazole, and radical surgery - case report and review of the literature. Neurosurgery 1995;36: 858-63.
39. Lupinetti FM, Behrendt DM, Giller RH, et al. Pulmonary resection for fungal infection in children undergoing bone marrow transplantation. J Thorac Cardiovasc Surg 1992;104:684-7.
40. Cordonnier C, Beaune J, Offner F, et al. Aspergillosis prior to bone marrow transplantation. Bone Marrow Transplant 1995;16:323-6.
41. Michailov G, Laporte JPh, Lesage S, et al. Autologous bone marrow transplantation is feasible in patients with a prior history of invasive pulmonary aspergillosis. Bone Marrow Transplant 1996;17:569-72.
42. Martino R, Nomdedeu J, Altes A, et al. Successful bone marrow transplantation in patients with previous invasive fungal infections: report of four cases. Bone Marrow Transplant 1994;13:265-69.
43. McWhinney PHM, Kibbler CC, Hamon MD, et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993;17:397-404.
44. Richard C, Romon I, Baro J, et al. Invasive pulmonary aspergillosis prior to BMT in acute leukemia does not predict a poor outcome. Bone Marrow Transplant 1993; 12:237-41.
45. Schattenberg A, De Vries F, De Witte T, et al. Allogeneic bone marrow transplantation after partial lobectomy for aspergillosis of the lung. Bone Marrow Transplant 1988; 3:509-12.
46. Goodrich JM, Reed EC, Mori M, et al. Clinical features and analysis of risk factors for invasive Candidal infection after marrow transplantation. J Infect Dis 1991;164:731-40.
47. Verfaillie C, Weisdorf D, Haake R, et al. Candida infections in bone marrow transplant recipients. Bone Marrow Transplant 1991;8:177-84.
48. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole vs. amphotericin B and review of the literature Clin Infect Dis 1996;23:964-72.
49. Wingard JR, Merz WG, Rinaldi MG, et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993;37:1847-9.
50. Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infections among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325: 1274-7.
51. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996;22(2 Suppl):S89-S94.
52. Hadfield TL, Smith MB, Winn RE, al. Mycoses caused by Candida lusitaniae Rev Infect Dis 1987;9:1006-12.
53. Wingard JR Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995;20:115-25.
54. Gelfand MS. Candida tropicalis. Infect Control Hosp Epidemiol 1989;10:280-3.
55. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
56. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-52.
57. Kunova A, Trupl J, Dluholucky S, et al. Use of fluconazole is not associated with a higher incidence of Candida krusei and other non-albicans Candida species. Clin Infect Dis 1995;21:226-7.
58. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30.
59. Anaissie EJ, Vartivarian SE, Abi-Said D, et al. Fluconazole vs. amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996;101: 170-6.
60. Milefchik E, Leal M, Haubrich R, et al. A Phase II dose escalation trial of high dose fluconazole with and without flucytosine for AIDS associated cryptococcal meningitis [abstract 5]. In: Proceedings and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections: January 22-26, 1997, Washington (DC) Alexandria (VA): Infectious Diseases Society of America, 1997:65.
61. Rex JH, Pfaller MA, Galgiani JN, et al. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Clin Infect Dis 1997;24:235-47.
62. Nolte FS, Parkinson T, Falconer DT, et al. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemo 1997;44:196-9.
63. Walsh TJ, Whitcomb PO, Revankar SG, et al. Successful treatment of hepatosplenic Candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995; 76:2357-62.
64. Tanaka J, Kasai M, Masauzi N, et al. Successful second allogeneic bone marrow transplantation in a relapsed acute myeloid leukemia patient with fungal liver abscess. Ann Hematol 1992;65:193-5.
65. Bjerke JW, Meyers JD, Bowden RA. Hepatosplenic candidiasis - a contraindication to marrow transplantation? Blood 1994;84:2811-4.